Evidence map›Paper›PMID 41767532›Full record

ReviewFrontiers in medicine2026

Diagnosis and treatment of sarcoidosis based on immunological etiology and mechanisms.

Jingshu Zhao, Lixuan Ma, Junwen Luan

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jingshu Zhao *Department of Pathogen Biology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Lixuan Ma *Department of Pathogen Biology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Junwen LuanDepartment of Pathogen Biology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary sarcoidosis is a multisystem disease characterized by non-caseating granulomas, and its pathogenesis involves genetic susceptibility and abnormal immune responses triggered by environmental antigens. This article reviews the immunological etiology and mechanisms of pulmonary sarcoidosis, systematically discussing its pathogenetic basis, core immune mechanisms, and the role of key immunological biomarkers (such as sIL-2R, CD4+/CD8+ ratio in BALF, and HRCT) in diagnosis and assessment. It also outlines the step-up therapy, ranging from glucocorticoids to immunomodulators, biologic agents, and emerging anti-fibrotic therapies, aiming to provide an immunological basis for the precise diagnosis and treatment of pulmonary sarcoidosis.

Indexed as

biomarkersimmune mechanismspathogenesispulmonary sarcoidosisstep-up therapy

Identifiers

PMID41767532
PMCPMC12935876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.